

1 **TITLE PAGE**

2

3 **Effects of oral anticoagulant adherence on stroke, death, and major**
4 **bleeding in patients with atrial fibrillation: A long-term**
5 **retrospective cohort study**

6

7 Abdollah Safari, PhD^a, Hamed Helisaz, PhD^{b,c}, Shahrzad Salmasi, PhD^d, Adenike Adelokun,
8 MSc^e, Mary A. De Vera, PhD^{e,f}, Jason G. Andrade, MD^{g,h,i,k}, Marc W. Deyell, MD MSc^{g,i,j},
9 Peter Loewen, PharmD^{e,f,i}

10

11 ^a School of Mathematics, Statistics, and Computer Science, College of Science, University of
12 Tehran, Iran

13 ^b Faculty of Applied Science, University of British Columbia

14 ^c GranTAZ Consulting Ltd., Vancouver, Canada

15 ^d McGill University, Montreal, Canada

16 ^e Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada

17 ^f Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences,
18 University of British Columbia, Canada

19 ^g Division of Cardiology, Faculty of Medicine, University of British Columbia, Vancouver,
20 Canada

21 ^h Atrial Fibrillation Clinic, Vancouver General Hospital, Canada

22 ⁱ UBC Center for Cardiovascular Innovation, Vancouver, Canada

23 ^j Centre for Health Evaluation & Outcome Sciences, Providence Health Care Research Institute,
24 Canada

25 ^k Montreal Heart Institute, Université de Montréal, Montréal, Canada

26

27 **Body word count:** 3499

28

29 **Funding:** This research was supported by Canadian Institutes of Health Research grant (FRN
30 168896). Dr. Loewen's research is also partially supported by the UBC David H MacDonald
31 Professorship in Clinical Pharmacy (Vancouver, Canada). Dr. Salmasi's research was supported
32 by a Canadian Institutes of Health Research Postdoctoral Fellowship award.

1

33 **Disclosure:** Dr. Andrade has received honoraria from Bayer, Biosense-Webster, BMS Pfizer,
34 Medtronic, and Servier, as well as Grants from Medtronic. Dr. Deyell has received honoraria
35 from Pfizer, Servier, and Bayer. Other authors have no conflicts of interest to disclose.

36 **Disclaimer:** Access to data provided by the Data Steward(s) is subject to approval, but can be
37 requested for research projects through the Data Steward(s) or their designated service providers.
38 All inferences, opinions, and conclusions drawn in this publication are those of the author(s), and
39 do not reflect the opinions or policies of the Data Steward(s).

40

41 Address for correspondence:

42 Peter Loewen B.Sc.(Pharm), ACPR, Pharm.D., FCSHP, R.Ph.
43 Associate Professor | Faculty of Pharmaceutical Sciences
44 David H MacDonald Professor in Clinical Pharmacy
45 Faculty, UBC Collaboration for Outcomes Research & Evaluation
46 Researcher, UBC Center for Cardiovascular Innovation
47 The University of British Columbia | Vancouver Campus
48 2405 Wesbrook Mall | Vancouver, BC Canada V6T 1Z3
49 phone 604 506 8011 | peter.loewen@ubc.ca

50

51 **Acknowledgements:** The authors are grateful to Dr. Anita I. Kapanen from University of British
52 Columbia for her expert support of the data stewardship and ethical oversight of this study.

53

54 **Disclaimer:** All inferences, opinions, and conclusions drawn in this manuscript are those of the
55 authors, and do not reflect the opinions or policies of the Data Steward(s).

56 **ABSTRACT**

57 **Background**

58 Patients with atrial fibrillation (AF) are frequently nonadherent to oral anticoagulants (OACs)
59 prescribed for prevention of stroke and systemic embolism (SSE). The effects of OAC adherence
60 on clinical outcomes are uncertain because previous studies used short time periods, treated
61 adherence as binary, and/or excluded VKA users. Our objectives were to quantify the
62 relationship between adherence to OACs as a continuous variable and AF-related clinical
63 outcomes, and to compare the consequences of nonadherence between OAC classes and
64 individual OACs.

65 **Methods**

66 This retrospective, observational cohort study included incident cases of AF from population-
67 based administrative data of 5 million British Columbians from 1996 to 2020. The exposure of
68 interest was proportion of days covered (PDC) for incident OAC prescriptions during 90 days
69 before a clinical event or end of follow-up. Multivariable Cox proportional hazard models were
70 used to evaluate time to first composite outcome of SSE, transient ischemic attack (TIA), or
71 death and SSE and several secondary outcomes. Models were also stratified by the OAC patients
72 were receiving within 90 days of the outcome event.

73 **Results**

74 The study cohort included 34,946 patients (mean age 70.1, 45% female) with median follow-up
75 of 6.7 years. Each 10% absolute decrease in PDC was associated with a 4.3% (95%CI 2.9-5.6)
76 and 10.3% (95%CI 7.5-13.0) increase in hazard of SSE, TIA, or death for VKA and direct OAC
77 (DOAC) users, respectively. For SSE, hazard increases per 10% PDC reduction were 22.5%
78 (95%CI 19.6-25.4) and 34.2% (95%CI 28.2-40.6) for VKA and DOAC, respectively. Similar
79 significant effects were seen for all secondary efficacy outcomes. Differences between VKA and
80 DOAC were statistically significant for all outcomes ($p < 0.001$ all contrast tests) except major
81 bleeding.

82 **Conclusions**

83 Even small reductions in OAC adherence in patients with AF are associated with significant
84 increases in risk of SSE and death, and these effects are significantly greater with DOAC
85 nonadherence than with VKA nonadherence. These results suggest that DOAC recipients are
86 more vulnerable than VKA recipients to increased risk of stroke and death even with small
87 reductions in adherence. The worsening efficacy outcomes associated with decreasing adherence
88 occur without any benefit in terms of major bleeding reduction.

89

90 INTRODUCTION

91 Atrial fibrillation (AF) is the most common chronic arrhythmia, affecting 3% of the world's
92 population.^{1,2} Stroke prevention is a cornerstone of AF management because patients with AF
93 are at 5 times higher risk of experiencing a stroke than those without AF, and strokes secondary
94 to AF are more debilitating and more lethal than those due to cerebrovascular disease.^{3,4} Oral
95 anticoagulants [OACs; vitamin K antagonists (VKAs, typically warfarin), Direct Oral
96 Anticoagulants (DOACs; apixaban, dabigatran, edoxaban and rivaroxaban)] are highly effective
97 for stroke prevention.⁵⁻⁸ Unfortunately, it is estimated that 33-50% of patients are nonadherent to
98 their OACs and miss, on average, 30% of their OAC doses.^{9,10}

99 It is important to quantify the relationship between OAC adherence and clinical outcomes in
100 patients with AF because the clinical consequences of nonadherence are potentially devastating
101 and costly. The few existing studies have treated adherence as a binary exposure (e.g. ≥ 80 or $<$
102 80%) and evaluated the effect of adherence over only short follow-up durations (< 2 years),¹¹⁻¹⁶
103 despite OAC therapy being lifelong and adherence being a continuous spectrum known to vary
104 over time.¹⁷ Existing studies have typically excluded VKA users because of difficulties in
105 measuring adherence due to its variable dosing regimens. It is conceivable that patients with
106 different levels of adherence who would otherwise be simply categorized as nonadherent
107 experience different clinical event rates, and that nonadherence to VKA vs. DOACs has
108 significantly different clinical consequences due to their different pharmacodynamics.¹⁸⁻²⁰
109 Hence, significant uncertainty remains about the relationship between OAC adherence and the
110 risk of stroke or systemic embolism (SSE) and death.

111 Given our limited understanding of the multidimensional nature of medication adherence,
112 reliable interventions to improve adherence in patients with AF remain elusive.^{9,21} A more
113 comprehensive understanding of these phenomena could help identify patients with adherence
114 problems who are most at risk of adverse clinical outcomes and could inform the design of
115 adherence interventions to maximize their impact on stroke and death.

116 To address these knowledge gaps, our objectives were to quantify the relationship between
117 adherence to OACs and various AF-related clinical outcomes, and to compare the consequences
118 of nonadherence to VKA to DOAC in terms of these outcomes.

119 METHODS

120 Study design and setting

121 This was a retrospective observational cohort study using de-identified patient records from
122 administrative data (Population Data BC²²) for the entire population of the province of British
123 Columbia (BC), Canada (~5 million residents). This included the following databases: Medical
124 Services Plan (MSP)²³ billing for outpatient visits, Discharge Abstract Database (DAD)²⁴
125 containing extensive data from hospitalizations, the Consolidation File²⁵ containing
126 demographics such as sex, place of residence, and registration with the provincial healthcare

127 plan, and the Vital Statistics Database²⁶ containing date and primary cause of death. Data for all
128 prescription medications dispensed outside of hospital between January 1996 and December
129 2019 was retrieved from the PharmaNet database and linked to the other datasets.²⁷ Person-level
130 linkage used a study-specific unique identifier created by the data provider and linkage was
131 performed before the data was released to the investigators.

132 The study was approved by the University of British Columbia Clinical Research Ethics Board
133 (H17-02420). Study reporting follows the Strengthening the Reporting of Observational Studies
134 in Epidemiology (STROBE) and Reporting of Studies Conducted Using Observational Routinely
135 Collected Health Data Statement for Pharmacoepidemiology (RECORD-PE) extension guides.<sup>28-
136 30</sup>

137 **Participants**

138 We created an incident cohort of adult patients ≥ 18 years old with non-valvular AF. Using the
139 algorithm validated by Navar et al. with a positive predictive value of 95.7%,³¹ we included
140 individuals who had ≥ 3 recorded visits in MSP or DAD^{23,24} related to AF or atrial flutter, with at
141 least one of the three recorded visits being AF-specific (ICD-9 = 427.31; ICD-10 = I48;
142 Supplemental Appendix A). To distinguish AF for which anticoagulation therapy is normally
143 considered from potentially transient/reversible AF, at least two of the visits had to occur within
144 one year.³²

145 Next, using Anatomical Therapeutic Chemical (ATC) codes from PharmaNet²⁷ records, we
146 captured all dispensed prescriptions for OACs available in the study jurisdiction (warfarin,
147 dabigatran, apixaban, rivaroxaban, edoxaban). Individuals were excluded if they did not have
148 continuous public medical insurance coverage during the 1-year prior to their first OAC
149 prescription fill, or if their first OAC prescription occurred before 1997 to permit 1-year baseline
150 covariate ascertainment, or after Jan 2019 to ensure ≥ 1 year follow-up before end of the data.

151 The date on which the first OAC prescription was filled after the first AF diagnostic code (or
152 within 60 days before the first AF code), was referred to as the “index date” (Figure 1). Baseline
153 patient characteristics were measured during 12 months prior to the index date, referred to as the
154 “baseline period”. Follow-up ended at the time of first study event or on the date of the last
155 available data, whichever came first.

156 To ensure we included only incident AF cases and incident OAC use, those with an AF code or
157 OAC prescription fill during the 3 years prior to their AF diagnosis date or their index date,
158 respectively, were excluded. To improve specificity, we excluded individuals with indications
159 for OAC other than non-valvular AF (e.g., venous thromboembolism, rheumatic valve disease;
160 Supplemental Appendix A) based on codes appearing any time before their index date. We also
161 excluded patients with two different OACs filled on the same index date. Finally, because ≥ 2
162 OAC prescription fills were required to measure adherence, patients with only one OAC
163 prescription fill were excluded.

164 Patients were followed from the index date until the end of their follow-up time, defined as
165 December 2019, date of death, or discontinuation of their public medical insurance enrolment,
166 whichever came first.

167 **Variables**

168 The primary exposure of interest was OAC adherence, measured as proportion of days covered
169 (PDC).³³⁻³⁵ Ninety-day consecutive windows (the typical length of dispensed prescriptions in
170 PharmaNet²⁷) were created for each patient between their first OAC prescription fill date and the
171 end of their follow-up and PDC was calculated for each window.³⁶ If a patient permanently
172 discontinued their medication, all windows after their last supply ran out were assigned a PDC of
173 zero until the end of their follow-up period. To address variable dosing of warfarin based on
174 international normalized ratio (INR) results, we used the validated Random Effects Warfarin
175 Days' Supply (REWarDS) method to estimate the average daily dose for warfarin in the
176 computation of PDC for warfarin.³⁷ PDC was multiplied by 10 (representing PDC deciles) to
177 allow more meaningful interpretation of its impact on risk of outcomes in our study models.
178 The co-primary outcomes were SSE and the composite of SSE, transient ischemic attack (TIA),
179 or death. Secondary outcomes were all-cause death, cardiovascular death, SSE or TIA, ischemic
180 stroke, hemorrhagic stroke, major bleeding, and nontraumatic intracranial hemorrhage. All
181 outcomes were measured as time to first event.

182 All outcomes except death were based on the first or second most responsible causes of
183 hospitalization as recorded in DAD.²⁴ Death and its cause were ascertained from the Vital
184 Statistics registry.²⁶ The primary outcome of SSE was chosen to align the Canadian
185 Cardiovascular Society's AF surveillance quality indicators program primary outcome and used
186 the same validated ascertainment scheme.^{38, 39} The other primary outcome was chosen to avoid
187 competing risk between SSE and death and included TIA using a validated ascertainment
188 scheme to encompass all stroke-related outcomes.⁴⁰

189 Covariates included in study analyses were age, sex, SSE risk score, CHA₂DS₂-VASc
190 (Congestive heart failure, Hypertension, Age ≥ 75 , Diabetes, prior Stroke or systemic embolism,
191 Vascular disease, Age 65-74, Sex [female]),⁴¹ major bleeding risk score, modified HAS-BLED
192 (Hypertension, Abnormal renal/liver function, Stroke, Bleeding, Labile INR, Elderly, and
193 Drugs/alcohol),^{42, 43} comorbidities (individual components of CHA₂DS₂-VASc and HAS-BLED
194 scores), socioeconomic status, neighbourhood income quintile, number of medical services plan
195 billings, number of hospitalizations, time from AF diagnosis to OAC start, Charlson comorbidity
196 index (CCI),⁴⁴ and polypharmacy (5 or more concurrent medications, not including OAC).⁴⁵
197 Following convention, CHA₂DS₂-VASc and HAS-BLED scores were binarized at ≥ 2 . Due to
198 their highly skewed distributions, number of hospitalizations during follow-up was grouped into
199 four categories: 0, 1, 2, and ≥ 3 admissions, and time to OAC initiation was grouped into three
200 categories: < 3 months, 3 to 9 months, and > 9 months. Multivariable imputation was used to
201 impute missing values for SES (the only covariate with missing values).

202 To enable analyses of association between specific OAC drugs and the study outcomes, we
203 created an additional variable for OAC at time of the event using a novel scheme described in
204 Supplemental Appendix A4. For our main exposure of interest, PDC, to study the effect of OAC
205 adherence and OAC drug class separately, we included their corresponding information in three
206 separate variables: PDC, OAC drug class, and individual OAC drug. The former measured
207 patients' adherence to any prescribed OAC medication calculated during 90-day window prior to
208 the event date or end of follow-up, and the others captured the class or drug temporally
209 associated with the event.

210 To avoid collinearity, we selectively included HAS-BLED, CHA₂DS₂-VASc, and CCI scores in
211 our study models based on their relevance. We used CHA₂DS₂-VASc score for stroke or death
212 outcomes and HAS-BLED score for bleeding outcomes. CCI was not included in any models
213 due to its high correlation with both scores.

214 **Statistical analyses**

215 To evaluate the association between OAC adherence and time to clinical outcomes, multivariable
216 Cox proportional hazard models were constructed that incorporated PDC and the study
217 covariates. To ensure clinical events were first occurrences, for models including stroke (any
218 type) or major bleeding, we excluded patients who had that event in the previous 5 years. For
219 each model, history of other study outcomes within the previous year was also included as a
220 covariate. For example, when stroke was among the model outcomes, history of major bleeding
221 was used as a covariate in the model, and vice-versa. For outcomes involving death, history of
222 stroke and major bleeding were both included in the model. For all analyses we used each
223 patient's OAC PDC during the 90-days prior to the event or end of follow-up, whichever came
224 first. Sex was included as a covariate in all models regardless of its contribution and we
225 constructed separate Cox models for females and males for the primary outcomes.

226 For our second objective, we hypothesized that the relationships between PDC and time to
227 clinical outcomes would vary significantly based on the OAC class (VKA or DOAC) and/or
228 OAC drug the patient was receiving at the time of their event.^{46, 47} We evaluated this in the initial
229 Cox models by examining the significance of the PDC covariate hazard ratio (HR) regardless of
230 patients' OAC drug class. Then, to allow the effect of PDC on the hazard of outcomes to be
231 different for patients under different OAC drug classes at event time, we fitted the Cox models
232 with an additional PDC:OAC class interaction term. We also did contrast analyses comparing the
233 PDC HRs between VKA and DOAC recipients. Cox models with adherence to individual OAC
234 drugs as covariates were constructed for the primary outcomes using similar methods.

235 Model results are presented with hazard ratios (HR) and 95% confidence intervals (95%CI) for
236 covariates. HRs of PDCs are changes in risk of outcome per 10% absolute increase in PDC. For
237 ease of interpretation, associations between PDC and study outcomes are also presented as
238 percent increase in hazard of outcome per 10% absolute decrease in PDC.

239 **Sensitivity analyses**

240 To identify period effects, we fitted the models on patients diagnosed after 2010 when both OAC
241 drug classes were available. To evaluate the scheme used to assign patients an OAC drug class at
242 event time, similar Cox models were fitted on only patients with a stable OAC (no recent drug
243 switches or stopped medications), and different gap times (5, 7, or 10 days) prior to event date
244 were used in the scheme to test their effects on classification and outcomes. To study the effect
245 of PDC on outcomes among only patients with an active OAC, we used similar Cox models but
246 excluded patients with no OAC at event date. Further sensitivity analyses were conducted to test
247 the robustness of the results against different pre-event PDC periods: 30 days and 180 days vs.
248 conventional 90-day windows. We evaluated the effects of excluding people with a prior similar
249 event by running the models without that exclusion criterion. Finally, to identify residual
250 confounding due to healthy adherer effects,^{48,49} we performed analyses using accidental death as
251 the falsification endpoint.⁵⁰

252 All analysis was conducted using R v4.0.5 (R Core Team, Vienna, Austria, 2021) and RStudio
253 v1.3.1039 (RStudio Team, Boston, US, 2020).

254 **RESULTS**

255 **Participants**

256 The cohort included 34,946 people; 44.5% were female, and average age was 70.1 (11.3).
257 Median follow-up time was 6.7 years (interquartile range (IQR): 4.0, 10.7). The median number
258 of OAC prescriptions filled during follow-up was 42 (IQR 20, 66) per patient. Other
259 characteristics of the included patients are shown in Table 1.

260 During follow up 14,136 SSE, TIA, or death events and 1928 SSE events occurred. Table 2
261 shows the number of events included and median time to event in each study model.

262 **Effects of OAC adherence on clinical outcomes**

263 Results of the time-to-event analyses of the effect of PDC on outcomes are shown in Table 3 and
264 Figure 2. Primary outcomes were modelled with and without the PDC:OAC drug class
265 interaction term and secondary outcomes were modeled only with the interaction term. Figure 3
266 illustrates the relationship between log relative hazard of the primary outcomes and PDC by
267 OAC class from the Cox regression models. The figure shows the stronger relationship between
268 PDC and the primary outcomes among DOAC recipients versus VKA recipients (steeper orange
269 lines), and the gap between orange and blue lines reflects more patients with higher risk of
270 outcomes were prescribed VKA versus DOAC.

271 There were too few events to model outcomes for nontraumatic ICH (179 events), and death due
272 to bleeding (305 events), AF (603 events), or stroke (803 events).

273

274

275 **Individual OAC analyses**

276 Effects of adherence to individual OACs on the primary outcomes are shown in Figure 4. Too
277 few participants were receiving edoxaban to include it in the models. Contrast testing revealed
278 significant differences in hazards for all three DOACs compared to VKA, except dabigatran vs.
279 VKA for SSE.

280 **Sex-based analyses**

281 Sex-specific Cox models showed that for females, a 10% absolute decrease in PDC for VKA was
282 associated with a 4.5% increase in hazard of SSE, TIA, or death (HR 0.957; 95%CI 0.939 –
283 0.977), and 10.3% increase in hazard for DOAC recipients (HR 0.907; 95%CI 0.873 – 0.943).
284 The corresponding models for males showed a 10% absolute decrease in PDC for VKA was
285 associated with a 4.2% increase in hazard of SSE, TIA, or death (HR 0.960; 95%CI 0.943 –
286 0.978), and 10.5% increase in hazard for DOAC recipients (HR 0.904; 95%CI 0.874 – 0.934).
287 Contrast between VKA and DOAC was significant in both sets of sex-specific models ($p < 0.017$).
288 For SSE, in the females-only Cox model, a 10% absolute decrease in PDC for VKA was
289 associated with a 21.7% increase in hazard of SSE (HR 0.822; 95%CI 0.794 – 0.850), and 32.1%
290 increase in hazard for DOAC recipients (HR 0.757; 95%CI 0.705 – 0.812). The corresponding
291 models for males showed a 10% absolute increase in PDC for VKA was associated with a 24.2%
292 increase in hazard of SSE (HR 0.805; 95%CI 0.778 – 0.833), and 36.2% increase in hazard for
293 DOAC recipients (HR 0.734; 95%CI 0.690 – 0.780). Contrast between VKA and DOAC was
294 significant in both sets of sex-specific models ($p < 0.039$).

295 **Sensitivity analyses**

296 Confining the primary analyses to patients who initiated OAC therapy after 2010, when at least
297 one alternative to VKA was available, had no significant effect on the model outputs. Choosing a
298 longer window of PDC prior to events (180 days) resulted in more model instability and sharply
299 reduced effect sizes, indicating clinical events are closely related to short-term OAC-taking
300 behaviours rather than long-term preventive effects, as hypothesized. Sensitivity analysis of the
301 robustness of our scheme to attribute drug classes to clinical events showed that different cut-offs
302 for number of days prior to events for drug changes (5d, 7d, 10d) did not affect the classification
303 proportions. Exclusion of patients with a prior similar event from study models had negligible
304 effects on the results (Supplemental Appendix A6.3, A6.4). The falsification analyses using
305 accidental death as an outcome showed no association with PDC, confirming healthy adherer
306 effects did not contribute significantly to our results.

307 **DISCUSSION**

308 In this large population-based cohort study of incident AF patients with incident OAC use, we
309 found strong associations between OAC adherence and major clinical outcomes. These
310 associations were markedly different between the OAC drug classes patients were prescribed at
311 the time of their event. For the primary outcomes, adherence to DOAC was significantly more

312 strongly associated with events than adherence to VKA, after adjustment for available
313 confounders. For DOACs, each 10% absolute decrease in adherence was associated with a
314 34.2% increase in risk of SSE and 10.3% increase in risk of SSE, TIA, or death. For VKA the
315 corresponding increased risks were 22.5% and 4.3%, respectively. Similar statistically significant
316 relationships were seen with secondary outcomes of SSE or TIA and ischemic stroke. These
317 effects were similar in magnitude among individual DOACs (dabigatran, apixaban, and
318 rivaroxaban). Strikingly, there was a strong association between DOAC adherence and all-cause
319 and cardiovascular death, which was not seen for VKA use.

320 These results confirm the importance of achieving maximal adherence in OAC recipients with
321 AF, but especially among DOAC recipients given the much sharper declines in efficacy we
322 observed for nonadherence to DOACs than for VKA. This may be a result of the short duration
323 of action of DOACs compared to VKA,⁵¹⁻⁵³ with missed DOAC doses potentially leaving
324 patients subtherapeutically anticoagulated for longer periods than missed VKA doses. Our results
325 are the first to demonstrate the magnitude of these effects on major clinical outcomes.

326 In an apparent paradox, higher adherence to OACs was associated with lower risk of major
327 bleeding. We conducted some exploratory analyses (e.g., examining only GI bleeding,
328 concurrent NSAID, antiplatelet, or gastroprotective drug therapy, further HAS-BLED stratum
329 analyses) to identify potential confounders, but this deserves further study. Residual confounding
330 is possible, for example from patients who are more adherent engaging in more bleeding risk-
331 reducing behaviours compared to less adherent patients (so-called healthy adherer effects),^{48, 49}
332 though our falsification endpoint analysis makes this less likely. The possibility that the
333 relationship between OAC adherence and major bleeding behaves differently than efficacy
334 outcomes deserves investigation. Regardless, we found no safety advantage to OAC
335 nonadherence, and our results clearly show that improving OAC adherence does not come at the
336 cost of more major bleeding.

337 Others have demonstrated that poor OAC adherence is associated with worse clinical outcomes
338 in patients with AF.¹¹⁻¹⁶ However, these prior studies had several methodological limitations
339 which ours overcomes: We used one of the world's most comprehensive administrative datasets
340 which includes complete medication prescribing records regardless of payer. We avoided
341 prevalent user biases with a new-user and incident cohort design.⁵⁴⁻⁵⁶ We achieved high
342 statistical power via our large sample size. We used adherence as a continuous variable,
343 revealing the effects of incremental and relatively small (e.g., 10%) changes in adherence, which
344 is not possible when adherence is treated as binary as it is in most studies. We used a rigorous
345 scheme to distinguish between OACs in use at the time of the event which allowed us to
346 compare effect estimates between OACs. Lastly, we included VKA recipients, a group routinely
347 excluded from population-based studies due to difficulties in accurately ascertaining PDC.

348 **Limitations**

349 These results should be interpreted considering the study's limitations. We assumed that filling a
350 prescription equates to consuming the medication, which may not always be true. Some variables

351 known to affect adherence (e.g., education level, adverse effects experienced, psychosocial
352 factors) were absent from the administrative databases, limiting our ability to account for their
353 contributions. Requiring at least two prescription fills for inclusion in the cohort meant that we
354 excluded those who never initiated therapy or stopped after one prescription fill, a potentially
355 high-risk subpopulation. The available data did not include laboratory values, so we were unable
356 to validate VKA adherence with INR values or include measures of renal function in study
357 models. There were too few edoxaban recipients and too few of certain events (ICH, deaths due
358 to bleeding, AF, or stroke) to permit analyses. Finally, our data covered only through the end of
359 2019, although this coincided with the beginning of the COVID-19 pandemic which resulted in
360 major changes to prescription filling and drug coverage for OACs in British Columbia. Hence,
361 our results are not confounded by those disruptions to the medication supply system and its
362 effects on prescribing and adherence.

363 **CONCLUSIONS**

364 Even small reductions in OAC adherence in patients with AF are associated with significant
365 increases in risk of SSE and death, and these effects are significantly greater with DOAC
366 nonadherence than with VKA nonadherence. These results suggest that DOAC recipients are
367 more vulnerable than VKA recipients to increased risk of stroke and death even with small
368 reductions in adherence. The worsening efficacy outcomes associated with decreasing adherence
369 occur without any benefit in terms of major bleeding reduction.

370

371

372 **KEY POINTS**

- 373 • Decreased OAC adherence in patients with AF is likely to yield significantly increased
374 risk of stroke and death, particularly among DOAC recipients.
- 375 • Even small reductions in OAC adherence are associated with increased risk of stroke and
376 death in AF patients.
- 377 • Negative effects of reduced OAC adherence on clinical outcomes are significantly greater
378 with DOACs than VKA, and DOAC recipients are more vulnerable than VKA recipients
379 to increased risk of stroke and death even with small reductions in adherence.
- 380 • Lower OAC adherence does not provide a safety advantage in terms of lower risk of
381 major bleeding.

382

383

384

385

386 REFERENCES

- 387 1. Lip GY, Brechin CM and Lane DA. The global burden of atrial fibrillation and stroke: a
388 systematic review of the epidemiology of atrial fibrillation in regions outside North America and
389 Europe. *Chest* 2012; 142: 1489-1498. 2012/03/31. DOI: 10.1378/chest.11-2888.
- 390 2. Morillo CA, Banerjee A, Perel P, et al. Atrial fibrillation: the current epidemic. *J Geriatr*
391 *Cardiol* 2017; 14: 195-203. DOI: 10.11909/j.issn.1671-5411.2017.03.011.
- 392 3. Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and
393 outcome of ischemic stroke: results from a population-based study. *Stroke* 2005; 36: 1115-1119.
394 2005/05/10. DOI: 10.1161/01.STR.0000166053.83476.4a.
- 395 4. Fang MC, Go AS, Chang Y, et al. Long-term survival after ischemic stroke in patients
396 with atrial fibrillation. *Neurology* 2014; 82: 1033-1037. DOI:
397 10.1212/WNL.0000000000000248.
- 398 5. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with
399 atrial fibrillation. *The New England Journal of Medicine*, 2013; 369: 2093-2104. DOI:
400 10.1056/NEJMoal310907.
- 401 6. Skanes AC, Healey JS, Cairns JA, et al. Focused 2012 update of the Canadian
402 Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and
403 rate/rhythm control. *The Canadian journal of cardiology* 2012; 28: 125-136. 2012/03/22. DOI:
404 10.1016/j.cjca.2012.01.021.
- 405 7. European Society of Cardiology. ESC guidelines for the management of atrial fibrillation
406 developed in collaboration with EACTS. *European Heart Journal*, 2016; 20. DOI:
407 10.1093/eurheartj/ehw210.
- 408 8. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the
409 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation.
410 *Journal of the American Heart Association*, ; 0: CIR.0000000000000665. DOI:
411 doi:10.1161/CIR.0000000000000665.
- 412 9. Salmasi S, Loewen PS, Tandun R, et al. Adherence to oral anticoagulants among patients
413 with atrial fibrillation: a systematic review and meta-analysis of observational studies. *BMJ*
414 *Open* 2020; 10: e034778. 2020/04/11. DOI: 10.1136/bmjopen-2019-034778.
- 415 10. Ozaki AF, Choi AS, Le QT, et al. Real-World Adherence and Persistence to Direct Oral
416 Anticoagulants in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis.
417 *Circ Cardiovasc Qual Outcomes* 2020; 13: e005969. 2020/03/10. DOI:
418 10.1161/circoutcomes.119.005969.
- 419 11. Alberts MJ, Peacock WF, Fields LE, et al. Association between once- and twice-daily
420 direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic
421 stroke. *Int J Cardiol*, 2016; 215: 11-13. 2016/04/23. DOI: 10.1016/j.ijcard.2016.03.212.
- 422 12. Deshpande CG, Kogut S, Laforge R, et al. Impact of medication adherence on risk of
423 ischemic stroke, major bleeding and deep vein thrombosis in atrial fibrillation patients using
424 novel oral anticoagulants. *Curr Med Res Opin* 2018; 34: 1285-1292. DOI:
425 10.1080/03007995.2018.1428543.
- 426 13. Borne RT, O'Donnell C, Turakhia MP, et al. Adherence and outcomes to direct oral
427 anticoagulants among patients with atrial fibrillation: findings from the veterans health
428 administration. *BMC Cardiovascular Disorders*, 2017; 17: 236. 2017/09/04. DOI:
429 10.1186/s12872-017-0671-6.

- 430 14. Shore S, Carey EP, Turakhia MP, et al. Adherence to dabigatran therapy and longitudinal
431 patient outcomes: insights from the veterans health administration. *American Heart Journal*,
432 2014; 167: 810-817. 2014/06/04. DOI: 10.1016/j.ahj.2014.03.023.
- 433 15. Yao X, Abraham NS, Alexander GC, et al. Effect of Adherence to Oral Anticoagulants
434 on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. *Journal of the*
435 *American Heart Association*; 5: e003074. DOI: 10.1161/JAHA.115.003074.
- 436 16. Alhazami M, Pontinha VM, Patterson JA, et al. Medication Adherence Trajectories: A
437 Systematic Literature Review. *J Manag Care Spec Pharm* 2020; 26: 1138-1152. 2020/08/29.
438 DOI: 10.18553/jmcp.2020.26.9.1138.
- 439 17. Gabet A, Chatignoux E, Grave C, et al. Stroke Incidence and Death in Atrial Fibrillation
440 Patients Newly Treated with Direct Oral Anticoagulants. *Clin Epidemiol* 2021; 13: 131-140.
441 2021/03/02. DOI: 10.2147/clep.S290707.
- 442 18. Baumgartner PC, Haynes RB, Hersberger KE, et al. A Systematic Review of Medication
443 Adherence Thresholds Dependent of Clinical Outcomes. *Frontiers in pharmacology* 2018; 9:
444 1290-1290. DOI: 10.3389/fphar.2018.01290.
- 445 19. Chen A, Stecker E and B AW. Direct Oral Anticoagulant Use: A Practical Guide to
446 Common Clinical Challenges. *J Am Heart Assoc* 2020; 9: e017559. 2020/06/17. DOI:
447 10.1161/jaha.120.017559.
- 448 20. Fawzy AM and Lip GYH. Pharmacokinetics and pharmacodynamics of oral
449 anticoagulants used in atrial fibrillation. *Expert Opinion on Drug Metabolism & Toxicology*
450 2019; 15: 381-398. DOI: 10.1080/17425255.2019.1604686.
- 451 21. Clarkesmith DE, Pattison HM, Khaing PH, et al. Educational and behavioural
452 interventions for anticoagulant therapy in patients with atrial fibrillation. *The Cochrane database*
453 *of systematic reviews* 2017; 4: Cd008600. 2017/04/06. DOI: 10.1002/14651858.CD008600.pub3.
- 454 22. British Columbia Ministry of Health. About Population Data BC,
455 <https://www.popdata.bc.ca/> (2021).
- 456 23. British Columbia Ministry of Health [creator] (2019). Medical Services Plan (MSP)
457 Payment Information File. V2. Population Data BC [publisher]. Data Extract. MOH (2020).
458 <http://www.popdata.bc.ca/data>.
- 459 24. Canadian Institute for Health Information [creator] (2019). Discharge Abstract Database
460 (Hospital Separations). V2. Population Data BC [publisher]. Data Extract. MOH(2020).
461 <http://www.popdata.bc.ca/data>.
- 462 25. British Columbia Ministry of Health [creator] (2020). Consolidation File (MSP
463 Registration & Premium Billing). V2. Population Data BC [publisher]. Data Extract.
464 MOH(2020). <http://www.popdata.bc.ca/data>.
- 465 26. British Columbia Ministry of Health [creator] (2020). Vital Events Deaths. V2.
466 Population Data BC [publisher]. Data Extract. MOH(2020). <http://www.popdata.bc.ca/data>.
- 467 27. British Columbia Ministry of Health [creator] (2020). PharmaNet. V2. BC Ministry of
468 Health [publisher]. Data Extract. Data Stewardship Committee(2020).
469 <http://www.popdata.bc.ca/data>.
- 470 28. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of
471 Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting
472 observational studies. *J Clin Epidemiol* 2008; 61: 344-349. 2008/03/04. DOI:
473 10.1016/j.jclinepi.2007.11.008.

- 474 29. Benchimol EI, Smeeth L, Guttmann A, et al. The REporting of studies Conducted using
475 Observational Routinely-collected health Data (RECORD) statement. *PLoS Med* 2015; 12:
476 e1001885. 2015/10/07. DOI: 10.1371/journal.pmed.1001885.
- 477 30. Langan SM, Schmidt SA, Wing K, et al. The reporting of studies conducted using
478 observational routinely collected health data statement for pharmacoepidemiology (RECORD-
479 PE). *Bmj* 2018; 363: k3532. 2018/11/16. DOI: 10.1136/bmj.k3532.
- 480 31. Navar-Boggan AM, Rymer JA, Piccini JP, et al. Accuracy and validation of an automated
481 electronic algorithm to identify patients with atrial fibrillation at risk for stroke. *Am Heart J*
482 2015; 169: 39-44 e32. DOI: 10.1016/j.ahj.2014.09.014.
- 483 32. Navar-Boggan AM, Rymer JA, Piccini JP, et al. Accuracy and validation of an automated
484 electronic algorithm to identify patients with atrial fibrillation at risk for stroke. *American heart*
485 *journal* 2015; 169: 39-44 e32. DOI: 10.1016/j.ahj.2014.09.014.
- 486 33. Centers for Disease Control and Prevention Division for Heart Disease and Stroke
487 Prevention. Calculating proportion of days covered (PDC) for antihypertensive and antidiabetic
488 medications: an ebaluation guide for grantees. . In: (NCCDPHP) NCfCDPaHP, (ed.). USA2015.
- 489 34. Karve S, Cleves MA, Helm M, et al. Prospective validation of eight different adherence
490 measures for use with administrative claims data among patients with schizophrenia. *Value*
491 *Health* 2009; 12: 989-995. 2009/05/01. DOI: 10.1111/j.1524-4733.2009.00543.x.
- 492 35. Karve S, Cleves MA, Helm M, et al. An Empirical Basis for Standardizing Adherence
493 Measures Derived from Administrative Claims Data among Diabetic Patients. *Medical care*
494 2008; 46: 1125-1133.
- 495 36. Hernandez I, He M, Chen N, et al. Trajectories of Oral Anticoagulation Adherence
496 Among Medicare Beneficiaries Newly Diagnosed With Atrial Fibrillation. *J Am Heart Assoc*
497 2019; 8: e011427. 2019/06/14. DOI: 10.1161/jaha.118.011427.
- 498 37. Salmasi S, Höegg T, Safari A, et al. SM1 The Random Effects Warfarin Days' Supply
499 (REWARDS) Model: Development and Validation of a NOVEL Method to Estimate Exposure
500 to Warfarin Using Administrative Data. *Value in Health* 2021; 24: S241. DOI:
501 10.1016/j.jval.2021.04.1210.
- 502 38. Sandhu RK, Wilton SB, Cruz J, et al. An Update on the Development and Feasibility
503 Assessment of Canadian Quality Indicators for Atrial Fibrillation and Atrial Flutter. *CJC Open*
504 2019; 1: 198-205. 2020/03/12. DOI: 10.1016/j.cjco.2019.05.007.
- 505 39. Cox JL, Dai S, Gong Y, et al. The Development and Feasibility Assessment of Canadian
506 Quality Indicators for Atrial Fibrillation. *Can J Cardiol* 2016; 32: 1566-1569. 2016/06/15. DOI:
507 10.1016/j.cjca.2016.02.059.
- 508 40. Leong M, Stang JM, McGuire N, et al. Regional Variation in Transient Ischemic Attack
509 and Minor Stroke in Alberta Emergency Departments. *Stroke* 2020; 51: 1820-1824. DOI:
510 doi:10.1161/STROKEAHA.119.027960.
- 511 41. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting
512 stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the
513 euro heart survey on atrial fibrillation. *Chest* 2010; 137: 263-272. 2009/09/19. DOI:
514 10.1378/chest.09-1584.
- 515 42. Lip GY, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for
516 predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED
517 (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition,
518 Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. *J Am Coll Cardiol* 2011; 57: 173-
519 180. 2010/11/30. DOI: 10.1016/j.jacc.2010.09.024.

- 520 43. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to
521 assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.
522 *Chest* 2010; 138: 1093-1100. 2010/03/20. DOI: 10.1378/chest.10-0134.
- 523 44. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in
524 ICD-9-CM and ICD-10 administrative data. *Med Care* 2005; 43: 1130-1139. 2005/10/15. DOI:
525 10.1097/01.mlr.0000182534.19832.83.
- 526 45. Masnoon N, Shakib S, Kalisch-Ellett L, et al. What is polypharmacy? A systematic
527 review of definitions. *BMC Geriatr* 2017; 17: 230. 2017/10/12. DOI: 10.1186/s12877-017-0621-
528 2.
- 529 46. Stauffer ME, Hutson P, Kaufman AS, et al. The Adherence Rate Threshold is Drug
530 Specific. *Drugs R D* 2017; 17: 645-653. DOI: 10.1007/s40268-017-0216-6.
- 531 47. Mekaj YH, Mekaj AY, Duci SB, et al. New oral anticoagulants: their advantages and
532 disadvantages compared with vitamin K antagonists in the prevention and treatment of patients
533 with thromboembolic events. *Ther Clin Risk Manag* 2015; 11: 967-977. 2015/07/08. DOI:
534 10.2147/term.S84210.
- 535 48. Ladova K, Vlcek J, Vytrisalova M, et al. Healthy adherer effect - the pitfall in the
536 interpretation of the effect of medication adherence on health outcomes. *J Eval Clin Pract* 2014;
537 20: 111-116. 2013/11/06. DOI: 10.1111/jep.12095.
- 538 49. Shrank WH, Patrick AR and Brookhart MA. Healthy user and related biases in
539 observational studies of preventive interventions: a primer for physicians. *J Gen Intern Med*
540 2011; 26: 546-550. 2011/01/05. DOI: 10.1007/s11606-010-1609-1.
- 541 50. Bijlsma MJ, Vansteelandt S, Janssen F, et al. The effect of adherence to statin therapy on
542 cardiovascular mortality: quantification of unmeasured bias using falsification end-points. *BMC*
543 *Public Health* 2016; 16: 303. 2016/04/14. DOI: 10.1186/s12889-016-2986-0.
- 544 51. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of
545 new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of
546 randomised trials. *Lancet* 2014; 383: 955-962. 2013/12/10. DOI: 10.1016/s0140-6736(13)62343-
547 0.
- 548 52. Stangier J and Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of
549 dabigatran etexilate, an oral direct thrombin inhibitor. *Clin Appl Thromb Hemost* 2009; 15 Suppl
550 1: 9s-16s. 2009/08/22. DOI: 10.1177/1076029609343004.
- 551 53. Fawzy AM and Lip GYH. Pharmacokinetics and pharmacodynamics of oral
552 anticoagulants used in atrial fibrillation. *Expert Opin Drug Metab Toxicol* 2019; 15: 381-398.
553 2019/04/06. DOI: 10.1080/17425255.2019.1604686.
- 554 54. Lund JL, Richardson DB and Stürmer T. The active comparator, new user study design in
555 pharmacoepidemiology: historical foundations and contemporary application. *Curr Epidemiol*
556 *Rep* 2015; 2: 221-228. 2016/03/10. DOI: 10.1007/s40471-015-0053-5.
- 557 55. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. *Am J*
558 *Epidemiol* 2003; 158: 915-920. 2003/10/31. DOI: 10.1093/aje/kwg231.
- 559 56. Luijken K, Spekrijse JJ, van Smeden M, et al. New-user and prevalent-user designs and
560 the definition of study time origin in pharmacoepidemiology: A review of reporting practices.
561 *Pharmacoepidemiol Drug Saf* 2021; 30: 960-974. 2021/04/27. DOI: 10.1002/pds.5258.
- 562 57. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the
563 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A Report
564 of the American College of Cardiology/American Heart Association Task Force on Clinical

565 Practice Guidelines and the Heart Rhythm Society. *Heart Rhythm* 2019; 16: e66-e93.
566 2019/02/01. DOI: 10.1016/j.hrthm.2019.01.024.
567 58. Lip GY and Lane DA. Stroke prevention in atrial fibrillation: a systematic review. *Jama*
568 2015; 313: 1950-1962. 2015/05/20. DOI: 10.1001/jama.2015.4369.
569 59. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for
570 the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management
571 of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm
572 Association. *Eur Heart J* 2012; 33: 2719-2747. 2012/08/28. DOI: 10.1093/eurheartj/ehs253.
573
574

575 **TABLES & FIGURES**

576

577 **Table 1: Characteristics of study patients at index date**

| Patient Characteristic | Overall (n = 34,946) | Males (n = 19,379) | Females (n = 15,567) |
|---|---------------------------------|-------------------------------|---------------------------------|
| Female | 15567 (44.5%) | | |
| Age, mean (SD) | 70.1 y ± 11.3 | 67.9 (11.5) | 72.9 (10.3) |
| Age category | | | |
| <55 | 3183 (9.1%) | 2445 (7.0%) | 738 (2.1) |
| 55-65 | 6983 (20.0%) | 4553 (13.0%) | 2430 (7.0%) |
| 65-75 | 11413 (32.7%) | 6400 (18.3%) | 5013 (14.3%) |
| ≥75 | 13367 (38.3%) | 5981 (17.1%) | 7386 (21.1%) |
| Neighborhood income quintile ^d | 3.0 ± 1.4 | 3.0 ± 1.4 | 2.8 ± 1.4 |
| Socioeconomic status category | | | |
| <2 | 7335 (21.0%) | 3722 (10.7%) | 3620 (10.4%) |
| 2-3 | 7132 (20.4%) | 3752 (10.7%) | 3393 (9.7%) |
| 3-4 | 6862 (19.6%) | 3873 (11.1%) | 2966 (8.5%) |
| ≥4 | 13617 (39.0%) | 8032 (23.0%) | 5588 (16.0%) |
| Index OAC | | | |
| Warfarin | 24927 (71.3%) | 13825 (39.6%) | 11102 (31.8%) |
| Dabigatran | 2601 (7.4%) | 1458 (4.2%) | 1143 (3.3%) |
| Rivaroxaban | 4714 (13.5%) | 2622 (7.5%) | 2092 (6.0%) |
| Apixaban | 2693 (7.7%) | 1469 (4.2%) | 1224 (3.5%) |
| Edoxaban | 11 (0.0%) | 5 (0.0%) | 6 (0.0%) |
| Characteristics measured during baseline period (1 year prior to index date) | | | |
| CHA ₂ DS ₂ -VASc score, median (IQR) ^e | 3 (2, 4) | 2 (1, 4) | 3 (2, 4) |
| HAS-BLED score, median (IQR) ^f | 2 (1, 3) | 2 (1, 3) | 2 (2, 3) |
| Weighted Charlson Comorbidity Index, median (IQR) ^g | 5 (3, 8) | 5 (3, 8) | 5 (3, 8) |
| Hypertension | 17546 (50.2%) | 10636 (30.4%) | 10108 (28.9%) |
| Vascular disease | 9723 (27.8%) | 5765 (16.5%) | 3958 (11.3%) |
| Diabetes | 6655 (19.0%) | 3992 (11.4%) | 2663 (7.6%) |
| Congestive heart failure | 5461 (15.6%) | 2951 (8.4%) | 2510 (7.2%) |

| | | | |
|---|-------------|-------------|-------------|
| Stroke/TIA | 3427 (9.8%) | 1692 (4.8%) | 1735 (5.0) |
| Abnormal renal function | 2248 (6.4%) | 1162 (3.3%) | 1086 (3.1%) |
| Major bleeding | 2778 (7.9%) | 1664 (4.8%) | 1114 (3.2%) |
| Abnormal liver function | 353 (1.0%) | 210 (0.6%) | 143 (0.4%) |
| Alcohol use | 213 (0.6%) | 170 (0.5%) | 43 (0.1%) |
| Prescribed nonsteroidal anti-inflammatory (NSAID) or antiplatelet drug, median (IQR) ^h | 0 (0-1) | 0 (0-1) | 0 (0-1) |

578 OAC: Oral Anticoagulants. TIA: Transient ischemic attack. IQR: Interquartile range.
579 Values are n (%), mean ± standard deviation, median (IQR), unless otherwise stated.
580 ^dNeighborhood income quintile represents the average equivalized disposable income by postal code in patients' residential
581 area at index date, with 1 as the lowest and 5 as the highest level.
582 ^eStroke risk score calculated based on the presence of comorbidities: Cardiomyopathy (1 point), Hypertension (1 point),
583 Age \geq 75 (2 points), Diabetes (1 point), Stroke (2 points), Vascular disease (1 point), Age 65–75 (1 point), Sex category female
584 (1 point). Scored if at least one disease specific ICD code was present in either outpatient or inpatient records during the
585 baseline period. Ascertainment scheme is in Supplemental appendix Table A1.
586 ^fBleeding risk score calculated based on the presence of comorbidities: Hypertension (1 point), Abnormal liver/kidney function
587 (1 point), Stroke (1 point), Bleeding (1 point), Age > 75 years (1 point), Drugs (NSAID or antiplatelet) or alcohol use (1 point).
588 Scored if at least one disease specific ICD code was present in either outpatient or inpatient records during the baseline period.
589 Ascertainment scheme is in Supplemental appendix Tables A1 and A2.
590 ^gEach comorbidity category has an associated weight (from 1 to 6), based on the adjusted risk of mortality or resource use, and
591 the sum of all the weights results in a single comorbidity score for a patient. Possible range of scores: 0-31. Zero indicates that
592 no comorbidities were found. Ascertainment scheme is in Supplemental appendix Table A1.
593 ^hNSAIDs and ASA could be obtained with or without a prescription in the study jurisdiction.
594
595

596 **Table 2: Study outcomes**

| Outcome model | Frequency | Median time to event in years (IQR) |
|--------------------------------------|------------------|--|
| Primary outcomes | | |
| SSE, TIA, or death* | 13,543 | 5.6 (2.8-9.5) |
| SSE* | 1804 | 4.3 (1.8-7.7) |
| Secondary outcomes | | |
| SSE or TIA* | 2377 | 4.2 (1.7-7.6) |
| Ischemic stroke* | 1467 | 4.2 (1.8-7.6) |
| Death (any cause) | 13,096 | 6.1 (3.2-10) |
| Cardiovascular death | 5306 | 6.3 (3.3-10.2) |
| Major bleeding** | 3839 | 3.7 (1.5-7.1) |
| Nontraumatic intracranial hemorrhage | 300 | 4.2 (1.8-7.3) |

597 SSE: stroke or systemic embolism. Ascertainment scheme in Supplemental appendix.

598 TIA: transient ischemic attack. Ascertainment scheme in Supplemental appendix.

599 *after excluding patients with SSE within the previous 5 years

600 **after excluding patients with major bleeding within the previous 5 years

601 Study outcome definitions are in Supplemental appendix Table A3.

602

603

604 **Table 3: Effects of OAC adherence on clinical outcomes by OAC class**

| Outcome | Number of events | Drug | HR (95% CI)* | Change in hazard of outcome per 10% absolute decrease in PDC (95%CI) | Contrast test for DOAC vs. VKA HR (95%CI); p-value | Detailed model outputs |
|--|------------------|---------|-----------------------|--|---|-----------------------------|
| SSE, TIA, or death (co-primary outcome) | 13,543 | any OAC | 0.992 (0.987 – 0.997) | 0.8% (0.3-1.3) increase | 0.946 (0.919-0.973); p<0.001 | Supplemental appendix A 6.1 |
| | | VKA | 0.959 (0.947 – 0.972) | 4.3% (2.9-5.6) increase | | Supplemental appendix A 6.3 |
| | | DOAC | 0.907 (0.885 – 0.930) | 10.3% (7.5-13.0) increase | | |
| SSE (co-primary outcome) | 1804 | any OAC | 0.901 (0.887 – 0.914) | 11% (9.4-12.7) increase | 0.913 (0.866-0.961); p<0.001 | Supplemental appendix A 6.2 |
| | | VKA | 0.816 (0.797 – 0.836) | 22.5% (19.6-25.4) increase | | Supplemental appendix A 6.4 |
| | | DOAC | 0.745 (0.711 – 0.780) | 34.2% (28.2-40.6) increase | | |
| SSE or TIA | 2377 | VKA | 0.824 (0.807 – 0.840) | 21.4% (19.0-23.9) increase | 0.926 (0.885-0.968); p<0.001 | Supplemental appendix A 6.5 |
| | | DOAC | 0.762 (0.732 – 0.794) | 31.2% (25.9-36.6) increase | | |
| Ischemic stroke | 1467 | VKA | 0.802 (0.780 – 0.824) | 24.7% (21.4-28.2) increase | 0.930 (95%CI 0.877-0.986); p=0.014 | Supplemental appendix A 6.6 |
| | | DOAC | 0.745 (0.708 – 0.785) | 34.2% (27.4-41.2) increase | | |
| All-cause death | 13,096 | VKA | 1.005 (0.986 | NS | 0.941 | Supplemental |

| | | | | | | |
|-------------------------|------|------|--------------------------|----------------------------------|---|-----------------------------------|
| | | | - 1.024) | | (0.907-0.977); p<0.001 | appendix A 6.7 |
| | | DOAC | 0.946 (0.916 - 0.977) | 5.7% increase | | |
| Cardiovascular death | 5306 | VKA | 0.999 (0.971 - 1.028) | NS | 0.919 (95%CI 0.869- 0.971); p=0.003 | Supplemental appendix A 6.8 |
| | | DOAC | 0.918 (0.875 - 0.963) | 8.9% (3.8- 14.3) increase | | |
| Major bleeding | 3839 | VKA | 0.850 (0.839 - 0.862) | 17.6% (16.0-19.2) increase | 1.019 (0.982- 1.058); p=0.317 | Supplemental appendix A 6.9 |
| | | DOAC | 0.863 (0.834 - 0.893) | 15.9% (9.3-19.9) increase | | |

605 *HRs are relative hazard per 10% increase in PDC.


606 NS: not statistically significant; SSE: stroke or systemic embolism; TIA: transient ischemic attack; VKA: vitamin K antagonist;

607 DOAC: direct-acting oral anticoagulant; PDC: proportion of days covered

608


609

610 **Figure 1: Study design**




611
612
613
614

615 **Figure 2: Increase in hazard of clinical event per 10% reduction in PDC by OAC**
616 **drug class**



617 *VKA vs. DOAC test for contrast $p < 0.001$
618 **VKA vs. DOAC test for contrast $p = 0.85$
619 SSE: stroke or systemic embolism; TIA: transient ischemic attack; VKA: vitamin K antagonist; DOAC: direct-acting
620 oral anticoagulant; PDC: proportion of days covered
621
622


623 **Figure 3: Change in log relative hazard of primary outcomes vs. PDC by OAC class**



624
625 SSE: stroke or systemic embolism; TIA: transient ischemic attack; VKA: vitamin K antagonist; DOAC: direct-acting oral
626 anticoagulant; PDC: proportion of days covered

627

628 **Figure 4: Increase in hazard of clinical event per 10% reduction in PDC by OAC**
629 **drug**



630
631

* test for contrast

632
633

